GlassScriptPhysician profile
Carmichael Rb John
NPI 1679080428
$3,381.11
in general payments reported to CMS, 2019-2025
20 companies · $842 in 2025
The $842 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $233 · 2022: $399 · 2023: $428 · 2024: $1,479 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519 · Travel and Lodging: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.71 |
| Travel and Lodging | $1,230.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $1,334.60 | 2024-2025 | Prevena, V.A.C. Dermatac, V.A.C. Veraflo |
| Astrazeneca Pharmaceuticals LP | $514.24 | 2021-2025 | Farxiga, Breztri |
| Amgen INC. | $374.79 | 2023-2025 | Evenity, Otezla |
| Novo Nordisk INC | $181.52 | 2021-2023 | Rybelsus, Ozempic |
| Convatec INC. | $174.33 | 2023-2025 | |
| Hollister Incorporated | $157.61 | 2025 | New Image, Adapt Ceraring |
| Smith+Nephew, INC. | $118.48 | 2023-2025 | Collagenase Santyl, Renasys Touch |
| Kerecis Limited | $85.33 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Hydrofera LLC | $79.59 | 2024-2025 | Hydrofera Blue, Hydrofera Blue Ready - Border |
| Merck Sharp & Dohme LLC | $75.38 | 2021-2022 | |
| Kci USA, INC. | $59.77 | 2023 | Activ.A.C. Ion Progress, Promogran Prisma, V.A.C. Veraflo |
| Lilly USA, LLC | $58.78 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Molnlycke Health Care US, LLC | $33.14 | 2024 | Mepitel One, Mepilex, Exufiber Ag+ |
| Bayer Healthcare Pharmaceuticals INC. | $32.82 | 2022 | |
| Abbott Laboratories | $28.11 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $19.17 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.87 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.63 | 2023 | Xifaxan |
| Pfizer INC. | $15.57 | 2021 | |
| Lifenet Health | $4.38 | 2024 | Theragenesis Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmichael John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.